212 related articles for article (PubMed ID: 12927947)
1. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management.
Calza L; Manfredi R; Chiodo F
Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947
[TBL] [Abstract][Full Text] [Related]
2. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
4. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
Calza L; Manfredi R; Chiodo F
AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532
[TBL] [Abstract][Full Text] [Related]
5. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Calza L; Manfredi R; Colangeli V; Tampellini L; Sebastiani T; Pocaterra D; Chiodo F
AIDS; 2005 Jul; 19(10):1051-8. PubMed ID: 15958836
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Calza L; Colangeli V; Manfredi R; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2016 Jun; 71(6):1451-65. PubMed ID: 26846208
[TBL] [Abstract][Full Text] [Related]
7. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.
Calza L; Manfredi R; Farneti B; Chiodo F
Int J Antimicrob Agents; 2003 Jul; 22(1):54-9. PubMed ID: 12842328
[TBL] [Abstract][Full Text] [Related]
8. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
9. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
Calza L; Manfredi R; Pocaterra D; Chiodo F
J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
[TBL] [Abstract][Full Text] [Related]
10. Management of dyslipidemia in patients with HIV disease.
Manfredi R
Clin Microbiol Infect; 2000 Nov; 6(11):579-84. PubMed ID: 11168060
[TBL] [Abstract][Full Text] [Related]
11. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
12. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
13. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
Calza L; Manfredi R; Chiodo F
Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and management of dyslipidemia in patients with HIV infection.
Green ML
J Gen Intern Med; 2002 Oct; 17(10):797-810. PubMed ID: 12390557
[TBL] [Abstract][Full Text] [Related]
15. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
Bucher HC; Young J; Battegay M
J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
[TBL] [Abstract][Full Text] [Related]
17. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
19. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
20. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
